Treatment of angiotensin receptor blocker-induced Angioedema: A case series

Laryngoscope

Volumn 125, Issue 7, 2015, Pages 1619-1623

  Strassen, Ulrich ^a   Bas, Murat ^a   Hoffmann, Thomas K ^b   Knopf, Andreas ^a   Greve, Jens ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Angioedema; angiotensin receptor blocker; B2 receptor antagonist; icatibant; Quincke edema

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CLEMASTINE; ICATIBANT; LOSARTAN; METHYLPREDNISOLONE; OLMESARTAN; PREDNISOLONE; PREDNISOLONE 21 HYDROGEN SUCCINATE; PREDNISONE; SUCCINIC ACID; UNCLASSIFIED DRUG; VALSARTAN; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; PREDNISOLONE SODIUM SUCCINATE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ERYTHEMA; FEMALE; HUMAN; HYPERTENSION; LARYNX EDEMA; MALE; MUSCLE HYPERTONIA; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SKIN BURNING SENSATION; SKIN IRRITATION; ANALOGS AND DERIVATIVES; ANGIOEDEMA; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG COMBINATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANGIOEDEMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONISTS; CLEMASTINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERTENSION; INJECTIONS, INTRAVENOUS; MALE; PREDNISOLONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84932199296     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.25163     Document Type: Article

References (35)

1. Powers B, Greene L, Balfe LM,. Updates on the treatment of essential hypertension: A summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. J Manag Care Pharm 2011; 17 (suppl 8): S1-S14.
2. White CM, Greene L,. Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. J Manag Care Pharm 2011; 17 (suppl 5): S1-S15.
3. Powers BJ, Coeytaux RR, Dolor RJ, et al., Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med 2012; 27: 716-729. doi: 10.1007/s11606-011-1938-8.
4. Slater EE, Merrill DD, Guess HA, et al., Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260: 967-970.
5. Bas M, Kojda G, Bier H, Hoffmann TK,. [ACE inhibitor-induced angioedema in the head and neck region. A matter of time?]. Article in German. HNO 2004; 52: 886-890.
6. Rai MR, Amen F, Idrees F,. Angiotensin-converting enzyme inhibitor related angioedema and the anaesthetist. Anaesthesia 2004; 59: 283-289.
7. Megerian CA, Arnold JE, Berger M,. Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment. Laryngoscope 1992; 102: 256-260.
8. Agah R, Bandi V, Guntupalli KK,. Angioedema: The role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med 1997; 23: 793-796.
9. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G,. Nonallergic angioedema: Role of bradykinin. Allergy 2007; 62: 842-856.
10. Hoover T, Lippmann M, Grouzmann E, Marceau F, Herscu P,. Angiotensin converting enzyme inhibitor induced angio-oedema: A review of the pathophysiology and risk factors. Clin Exp Allergy 2010; 40: 50-61.
11. Bas M, Greve J, Stelter K, et al., Therapeutic efficacy of icatibant in angioedema induced by angiotesin-converting enzyme inhibitors: A case series. Ann Emerg Med 2010; 56: 278-282.
12. Bas M, Bier H, Greve J, Kojda G, Hoffmann TK,. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy 2006; 61: 1490-1492.
13. Beavers CJ, Dunn SP, Macaulay TE,. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother 2011; 45: 520-524.
14. Hamasaki H, Hiraishi C, Yanai H,. Severe angioedema induced by angiotensin II receptor blocker. Int J Cardiol 2013; 168: e15-e16.
15. Kazim SF, Shahid M,. Losartan associated anaphylaxis and angioneurotic oedema. J Pak Med Assoc 2010; 60: 685-686.
16. van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J,. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998;158: 2063-2065.
17. Nykamp D, Winter EE,. Olmesartan medoxomil-induced angioedema. Ann Pharmacother 2007; 41: 518-520.
18. Kalra A, Cooley C, Palaniswamy C, Kalra A, Zanotti-Cavazzoni SL,. Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: Case report and literature review. Am J Ther 2012; 19: e189-e192.
19. Lo KS,. Angioedema associated with candesartan. Pharmacotherapy 2002; 22: 1176-1179.
20. Toh S, Reichman ME, Houstoun M, et al., Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012; 172: 1582-1589.
21. Caballero T, Baeza ML, Cabanas R, et al., Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol 2011; 21: 333-347; quiz follow 347.
22. Bas M, Hoffmann TK, Kojda G, Bier H,. [ACE-inhibitor induced angioedema]. Article in German. Laryngorhinootologie 2007; 86: 804-808, quiz 809-813.
23. Cohen DL, Townsend RR,. Can an angiotensin receptor blocker be used in a patient in whom angioedema developed with an angiotensin-converting enzyme inhibitor? J Clin Hypertens (Greenwich) 2008; 10: 949-950.
24. Weir MR,. Effects of renin-angiotensin system inhibition on end-organ protection: Can we do better? Clin Ther 2007; 29: 1803-1824.
25. Carey RM, Wang ZQ, Siragy HM,. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155-163.
26. Sosa-Canache B, Cierco M, Gutierrez CI, Israel A,. Role of bradykinins and nitric oxide in the AT2 receptor-mediated hypotension. J Hum Hypertens 2000; 14 (suppl 1): S40-S46.
27. Taylor AA, Siragy H, Nesbitt S,. Angiotensin receptor blockers: Pharmacology, efficacy, and safety. J Clin Hypertens (Greenwich) 2011; 13: 677-686.
28. Campbell DJ, Krum H, Esler MD,. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005; 111: 315-320.
29. Bonde MM, Olsen KB, Erikstrup N, et al., The angiotensin II type 1 receptor antagonist Losartan binds and activates bradykinin B2 receptor signaling. Regul Pept 2011; 167: 21-25.
30. Bas M, Hoffmann TK, Kojda G,. Evaluation and management of angioedema of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2006; 14: 170-175.
31. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE, III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-1063.
32. Davis AE, III. The pathogenesis of hereditary angioedema. Transfus Apher Sci 2003; 29: 195-203.
33. Chiu AG, Krowiak EJ, Deeb ZE,. Angioedema associated with angiotensin II receptor antagonists: Challenging our knowledge of angioedema and its etiology. Laryngoscope 2001; 111: 1729-1731.
34. Cicardi M, Banerji A, Bracho F, et al., Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
35. Bork K, Hardt J, Witzke G,. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130: 692-697.